Featuring exclusive articles, images, video, and more, DateWithHistory is your source for the most recent celebrity and tech news
25 Ozempic (semaglutide 1 mg once weekly (QW)) is the most recently registered GLP-1R monoagonist for the management of T2D, and was approved by the EMA in 2018, and by the FDA in 2017 (Fig. 2). In the SUSTAIN trials, Ozempic was well tolerated (Tables 1 and 2), and at its ...